UCB/N fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
UCB/N does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company